INTS vs UNH

Intensity Therapeutics (INTS) remains an extremely high-risk, high-reward clinical-stage oncology biotech. While recent full-year 2025 results reported (March 27, 2026) show a narrowed net loss and an extended cash runway to Q2 2027, alleviating immediate liquidity concerns, the core challenges persist. Early Phase 2 data for INT230-6 continues to show promise (75% disease control rate), and Swiss...

UnitedHealth Group (UNH) remains a healthcare titan, but its sheer scale and the highly regulated nature of its operations fundamentally limit its 10x growth potential within 3-5 years. The recent Optum Health operating loss of $278M in 2025 (compared to $7.77B income in 2024) is a significant concern, eroding the growth narrative that Optum once provided. Furthermore, the proposed 0.09% Medicare ...